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Tuberculosis (TB) remains a challenging global health concern and claims more than a
million lives every year. We lack an effective vaccine and understanding of what constitutes
protective immunity against TB to inform rational vaccine design. Moreover, treatment of
TB requires prolonged use of multi-drug regimens and is complicated by problems of
compliance and drug resistance. While mostMycobacterium tuberculosis (Mtb) bacilli are
quickly killed by the drugs, the prolonged course of treatment is required to clear
persistent drug-tolerant subpopulations. Mtb’s differential sensitivity to drugs is, at least
in part, determined by the interaction between the bacilli and different host macrophage
populations. Therefore, to design better treatment regimens for TB, we need to
understand and modulate the heterogeneity and divergent responses that Mtb bacilli
exhibit within macrophages. However, developing drugs de-novo is a long and expensive
process. An alternative approach to expedite the development of new TB treatments is to
repurpose existing drugs that were developed for other therapeutic purposes if they also
possess anti-tuberculosis activity. There is growing interest in the use of immune
modulators to supplement current anti-TB drugs by enhancing the host’s
antimycobacterial responses. Ion channel blocking agents are among the most
promising of the host-directed therapeutics. Some ion channel blockers also interfere
with the activity of mycobacterial ef!ux pumps. In this review, we discuss some of the ion
channel blockers that have shown promise as potential anti-TB agents.
Keywords: mycobacterium, tuberculosis, host-directed therapies, ion channel blocker, ef!ux pump,
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INTRODUCTION
Tuberculosis (TB) is an airborne infection contracted by inhalation of droplet nuclei containing
viable Mycobacterium tuberculosis (Mtb) that are released into the air by a person with active
pulmonary TB. The disease has been a major cause of morbidity andmortality for several millennia (1).
In 2019 alone, 10 million people developed active TB and 1.4 million of them died of the disease (2).
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Most of the TB cases in 2019 were in South-East Asia (44%), Africa
(25%) and western Paci!c (18%) (2).
TB is challenging to treat even though there are now more
than 20 !rst- and second-line anti-TB drugs in clinical use (3).
Current anti-TB treatment regimens utilize combinations of no
less than 3 drugs that must be taken for at least 6 months (3). The
lengthy treatment duration and side effects of the drugs often
lead to poor compliance with treatment, unfavorable outcomes
and development of drug-resistant Mtb strains (4). In 2019, more
than 0.5 million people developed multidrug-resistant (MDR) or
rifampicin (RIF)-resistant (RR) TB worldwide (2). Treatment of
drug-resistant TB requires longer and more complex drug
regimens, and often causes more serious adverse effects than
treatment of drug-susceptible TB (5). Current TB drugs target
the pathogen and function by compromising the structural
integrity or metabolic machinery of Mtb. In the last few years,
host-directed therapy (HDT) targeting macrophages has
emerged as a promising therapeutic strategy for both drug-
susceptible TB and MDR-TB.
In the lung, alveolar macrophages (AMs) are among the most
important innate defenses against Mtb. They phagocytose and
eliminate bacteria through various pathways including
phagosome maturation, autophagy and apoptosis. However,
Mtb has evolved to survive inside macrophages by corrupting
macrophage antimicrobial responses. HDTs for TB aim to rectify
or circumvent the corrupted antimycobacterial responses.
Ion channel blockers are among the most promising potential
HDTs for TB (Table 1). They are a diverse group of compounds
that alter cell physiology by attenuating ion currents across
cellular and subcellular membranes, and are most commonly
used to treat noncommunicable diseases such as hypertension.
Several Food and Drug Administration (FDA)-approved ion
channel blocking agents have shown promise at both
enhancing Mtb clearance by the immune system and
attenuating in"ammation in vitro and in animal models of TB
(Figure 1). Additionally, some ion channel blocking agents have
direct antimycobacterial activity. Here we review ion channel
blocking agents that have demonstrated anti-tuberculosis activity
in Mtb-infected macrophages and/or in animal models of TB.




Calcium ions (Ca2+) act as second messengers in several signal
transduction pathways (24). Calcium is more abundant in the
extra cellular "uid (ECF) than in the cytosol (25). In the cell,
most of the Ca2+are sequestered in endoplasmic reticuli (ER)
(25). Cell activation signals induce the "ow of Ca2+ from the ER
and ECF into the cytosol through channels such as inositol-1,4,5-
trisphosphate receptors (IP3Rs), ryanodine receptors (RyRs),
voltage-gated calcium channels (VGCC) and calcium release-
activated calcium (CRAC) channels.
Ca2+ signaling is important in antimycobacterial responses,
including autophagy, phagosome maturation and apoptosis. In
general, high cytosolic concentrations of Ca2+ promote
phagosome maturation and acidi!cation of mycobacteria-
containing phagosomes, necrosis and apoptosis; while cell
autophagy can be both upregulated or downregulated by Ca2+
(26–28). Whether Ca2+ in"ux upregulates or downregulates
autophagy depends on factors such as the biological context
and the ion channel conducting the Ca2+ current. For example,
Ca2+ currents through the ATP-gated cation channel P2X7
receptor enhanced autophagy and intracellular killing of M.
bovis-BCG in human macrophages, while currents through
VGCCs inhibit autophagy (26, 28).
TABLE 1 | Progress towards clinical use of ion channel blockers as anti-tuberculosis agents.
Year Milestone Reference
1990 Crowle and May demonstrated that chloroquine inhibits Mtb growth in macrophage cultures and potentiates streptomycin, pyrazinamide and
isoniazid
(6)
1992 Crowle and colleagues observed that chlorpromazine was more active against Mtb in macrophage cultures than in broth (7)
1993 Klemens and colleagues reported that clofazimine was effective against an MDR-TB strain in mice (8)
1994 Gollapudi and colleagues demonstrated that verapamil improves accumulation of INH in Mtb-infected macrophages and promotes sensitivity of Mtb
to INH
(9)
1996 Grange and Snell demonstrated that ambroxol has antimycobacterial activity in macrophages (10)
2003 Esiobu and Hoosein observed that sodium valproate inhibits growth of Mycobacterium smegmatis in broth (11)
2007 Byrne and colleagues observed that ketoconazole was synergistic with rifampicin-isoniazid-pyrazinamide (12)
2010 van Deun and colleagues successfully used clofazimine as part of a 9-month MDR-TB treatment regimen in a clinical trial (13)
2013 Smolarz and colleagues demonstrated that resveratrol has antitubercular activity in broth (14)
2014 Stanley and colleagues demonstrated that !uoxetine promotes autophagic control of Mtb in macrophages (15)
2015 Schiebler and colleagues successfully reduced the bacteria burden in mice infected with MDR-TB using carbamazepine and valproic acid (16)
2016 Machado and colleagues successfully used verapamil, thioridazine and chlorpromazine to decrease bacteria burden in Mtb-infected macrophages (17)
2016 WHO conditionally recommended a short course MDR-TB treatment regimen containing clofazimine (18)
2018 Choi and colleagues demonstrated that ambroxol promotes autophagy and potentiates rifampicin in murine models of TB (19)
2018 Rao and colleagues demonstrated that sodium valproate has antimycobacterial activity in broth and in macrophages in culture, and enhances
activity of rifampicin and isoniazid
(20)
2019 Roca and colleagues demonstrated that dantrolene inhibits necrotic death and promotes Mtb control in Mtb-infected macrophages (21)
2019 Yang and colleagues demonstrated that resveratrol has antitubercular activity in mice (22)
2021 Lee and colleagues observed that the use of calcium channel blockers was associated with a 32% decrease in the risk of active tuberculosis (23)
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A recent population-based analysis investigated whether
the use of calcium channel blockers modi!es the risk of active
TB among patients with heart failure or cerebrovascular
diseases in the clinical setting (23). The analysis included
8164 new active TB patients and 816,400 controls treated
with or without calcium channel blockers compared with b-
blockers or loop diuretics. Overall, the use of calcium channel
blockers was associated with a 32% decrease in the risk of
active TB [relative risk (RR), O.68 (95% CI, 0.58-0.78)] after
adjustment with disease risk score. Analysis of the effect of
different types of calcium channel blockers revealed that use of
dihydropyridine calcium channel blockers was associated with
a lower risk of TB [RR, 0.63 (95% CI, 0.53-0.79)] than non-
dihydropyridine calcium channel blockers [RR, 0.73 (95% CI,
0.54-0.94)]. b-blockers or loop diuretics were not associated
with lower risk of TB [RR, 0.99 (95% CI, 0.83-1.12)] and [RR,
0.88, (95% CI. 0.62-1.26)], respectively (23). This is the !rst
large population-based study to con!rm that calcium channel
blockers modify and reduce the risk of active TB in humans.
Therefore, modulating Ca2+ signaling using calcium channel
blockers is an attractive host-directed therapeutic strategy for
TB. Dantrolene, resveratrol and verapamil are the calcium
channel blockers that have shown the most promise as
potential anti-TB agents.
Dantrolene
Dantrolene is a RyR antagonist clinically approved for treatment
of malignant hyperthermia. RyRs are intracellular Ca2+ channels
that mediate the release of Ca2+ from the ER in response to
elevated cytosolic Ca2+ levels (29). They are important in
physiological and pathological processes, including necrosis
and apoptosis. Apoptosis involves enzymatic degradation of
intracellular contents including most of the phagocytosed
bacteria, and their packaging into fragments called apoptotic
bodies (30, 31). In contrast, necrosis involves swelling of
organelles, loss of plasma membrane integrity and release of
intracellular contents into the extracellular space (30). Mtb is
able to continue growing inside necrotic macrophages,
promoting lung in"ammation and parenchymal injury (32).
Mtb inhibits apoptotic cell death and promotes death of
infected macrophages by necrosis (32). Roca et al .
demonstrated the importance of ER-mitochondria signaling
relay involving RyR and plasma membrane L-type Ca2+
channels for TNF-mediated necrosis of Mtb-infected
macrophages in a zebra!sh model of TB. Dantrolene reduced
TNF-induced necrotic death of Mtb-infected macrophages by
more than 50% by attenuating RyR activity and the surge in
cytosolic Ca2+ that normally precedes necrosis, attesting to
its potential as a HDT for TB (21). Inhibition of RyR activity
A B C
FIGURE 1 | Mechanism of action of ion channel blockers. (A) Chloroquine, ketoconazole, phenothiazines and verapamil inhibit eukaryotic ef!ux systems, allowing
anti-TB drugs to achieve higher concentrations inside Mtb-infected host cells. Mtb promotes necrotic death of infected macrophages, leading to release of the
bacteria into the extracellular space, where the bacteria continue to proliferate in the necrotic cells or infect new cells. In contrast, apoptotic cell death leads to
enzymatic degradation of most of the bacteria. Dantrolene prevents necrotic death of Mtb-infected macrophages. (B) Phagocytosed Mtb (1) can also be eliminated
through phagosome maturation and autophagy. In autophagy, isolation membranes (2) elongate and engulf phagosomes. The autophagosome-sequestered
phagosomes (3) then fuse with lysosomes (4) to form autophagolysosomes (5), following which the lysosomal enzymes degrade the phagocytosed bacteria.
Ambroxol, resveratrol, verapamil, !uoxetine, carbamazepine and valproic acid promote autophagy. In phagosome maturation, Mtb phagosomes fuse with lysosomes
to form phagolysosomes (6). Phenothiazines promote acidi"cation of phagolysosomes, thus enhancing activity of the lysosomal enzymes. In contrast, chloroquine
inhibits phagosome maturation, thus preventing redox-induced Mtb drug tolerance, making the bacteria more susceptible to anti-TB drugs. (C) Phenothiazines and
verapamil can also inhibit Mtb metabolism and ef!ux pump activity. Clofazimine, a second-line anti-TB agent, also inhibits Mtb metabolism. Created with
BioRender.com.
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with dantrolene has also been shown to promote autophagy
(33), although this has not been demonstrated in Mtb-
infected macrophages.
Resveratrol
Resveratrol (3, 5, 4!!trihydroxystilbene) is a natural polyphenol
produced by plants including grapes and berries and widely used
as a food supplement (34, 35). It interacts with and modulates the
activity of at least 20 mammalian proteins including CRAC
channels and VGCCs (36). Resveratrol attenuates Mtb-induced
in"ammatory responses and enhances elimination of Mtb in
macrophages, at least in part by upregulating the expression of
host sirtuin 1 (37–39). Sirtuin 1 is a nicotinamide adenine
dinucleotide (NAD+)-dependent deacetylase that deactivates
ReLA, the p65 subunit of nuclear factor kappa B (NF-kB) (40).
NF-kB is a transcription factor important in the maturation of
dendritic cells, M1 polarization of macrophages, differentiation
of Th0 cells to the Th1 phenotype and expression of pro-
in"ammatory cytokines including IL-1, IL-8 and TNF-a (41,
42). Mtb down-regulates expression of host sirtuin 1 in
monocytes/macrophages, in mouse models of TB and in TB
patients with active disease, leading to overexpression of NF-kB
(40). While NF-kB expression is generally associated with anti-
TB responses, NF-kB also inhibits apoptosis and autophagy, two
of the pathways most effective at eliminating intracellular Mtb
(43). Recently, Cheng et al. reported a log fold decrease in
bacteria load after treating THP-1 cells infected with W148, an
MDR-TB strain, with resveratrol for 3 days (40).
Verapamil
Verapamil is an L-type calcium channel (LTCC) blocker widely
used for the treatment of hypertension, angina and abnormal
heart rhythms. LTCCs are a subfamily of VGCCs, and are
expressed on the plasma membrane of most cell types. Ca2+
currents through LTCCs inhibit release of ER calcium stores in
macrophages, thus attenuating Ca2+-dependent signaling
processes including macrophage activation (44). A previous
study demonstrated that Mtb induces up-regulation of VGCCs
in macrophages and dendritic cells to circumvent immune
responses (44). Inhibiting LTCC currents in Mtb-infected
macrophages with verapamil increases the concentration of
Ca2+ in the cytosol, leading to upregulation of autophagy and
Mtb killing (45–47).
The LTCC blockers verapamil and nifedipine also modulate
iron metabolism by mobilizing iron from tissues, reducing intra-
macrophage iron concentration and enhancing urinary iron
excretion (48, 49). Iron is a cofactor in numerous biochemical
reactions and is an essential nutrient for growth, replication and
pathogenicity of many intracellular pathogens including Mtb (50).
Further, prolonged iron overload promoted insulin resistance in
skeletal muscle cells in vitro and in vivo in a mouse model of iron
overload by inhibiting mTORC1 activation on autolysosomes and
interfering with autophagic lysosomal regeneration (51).
Therefore, by limiting iron availability, LTCC blockers promote
a key pathway to enhance host resistance and clearance of
intracellular pathogens such as Mtb.
In addition to enhancing host mycobacterial responses,
Verapamil is bactericidal to both replicating and non-
replicating Mtb in broth (52). It also inhibits both host and
bacterial ef"ux pumps and is synergistic with RIF and isoniazid
(INH) in broth, in macrophage cultures and in mouse models of
TB (17, 52, 53). Gupta and colleagues reported that
supplementing standard TB therapy with verapamil yielded an
extra 1.15 log CFU reduction in pulmonary bacterial load in a
murine model of TB (54).
Progress Towards Clinical Use of Calcium Channel
Blockers as Anti-Tuberculosis Agents
While evidence from in vitro and animal models of TB indicates
that calcium channel blockers have anti-TB activity, there has
been no progress in transitioning from pre-clinical !ndings to
clinical practice. The use of dantrolene as an anti-TB agent could
prove challenging due to its numerous adverse effects which
include muscle weakness, sedation, visual disturbances and
hallucinations (55). Compared to dantrolene, verapamil and
resveratrol are generally well tolerated and would be the
preferred compounds for repurposing as anti-TB agents.
Therefore, there is need for human clinical trials to assess the
ef!cacy of verapamil and resveratrol as clinically relevant adjunct
HDTs for TB.
Potassium Channel Blockers
While Ca2+ directly modulate antimycobacterial responses,
potassium (K+), sodium (Na+) and chloride (Cl-) ions
primarily modulate macrophage responses by modulating
Ca2+ currents.
K+ currents promote autophagy and other anti-TB responses
in Mtb-infected macrophages (28). K+ is more abundant in the
cytosol than the ECF while Ca2+, Na+ and Cl- are more abundant
in the ECF than the cytosol. This creates an overall negative
charge inside the cell relative to the ECF. The electrochemical
gradient between the cytosol and ECF facilitates movement of
calcium into the cytosol during macrophage activation. Outward
K+ currents help sustain Ca2+ entry and macrophage activation
by preventing plasma membrane (PM) depolarization and
maintaining an electrical gradient between the ECF and cytosol
(56, 57). Several K+ channel antagonists have shown promise as
potential anti-TB drugs, but most appear to promote
macrophage anti-TB responses by mechanisms remote from
ion channel blockade. Such compounds include chloroquine,
ketoconazole and clofazimine.
Chloroquine
Chloroquine has been in use as an antimalarial agent for over 5
decades. It also suppresses the activity of mammalian delayed
recti!er K+ channels (Kv1.3) in leukocytes and lymphocyte
production of pro-in"ammatory cytokines (58). Chloroquine
has anti-in"ammatory and immunomodulatory properties and
is used to treat autoimmune diseases including rheumatoid
arthritis and systemic lupus erythematosus. In addition,
chloroquine has engendered interest as a potential HDT
against several viral diseases.
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Mishra and colleagues observed a modest reduction in growth
of intracellular Mtb following exposure to chloroquine alone, but
a !ve-fold increase in the activity of INH when the two
compounds were used together (59). The combination of
chloroquine with INH eliminated Mtb within 8 weeks in a
murine model of TB, while INH alone only reduced bacterial
load by 2 logs during the same timeframe. Additionally,
chloroquine eradicated drug-tolerant Mtb, ameliorated lung
pathology and reduced post-treatment TB relapse in in vivo
mouse models of TB (59).
Chloroquine enhances the activity of INH through at least
two divergent pathways. First, it inhibits phagosome
acidi!cation, thus reducing redox-induced Mtb drug tolerance
(59). Second, chloroquine increases the intramacrophage
concentration of INH by inhibiting the activity of p-
glycoprotein and breast cancer resistance protein-1 (BCRP-1)
(60, 61). P-glycoprotein and BCRP-1 are mammalian ef"ux
pumps that are overexpressed in Mtb infected macrophages,
where they extrude anti-TB drugs into the ECF, thus protecting
the intracellular bacteria from the antibiotics (62). Together,
these studies suggest potential for repurposing chloroquine to
shorten the duration of current TB treatment and to achieve
relapse-free cure.
Ketoconazole
Ketoconazole is an azole antifungal used to treat cutaneous and
systemic fungal infections. It kills fungi by inhibiting synthesis of
ergosterol, an essential component of the fungal PM (63).
Ketoconazole also inhibits the activity of voltage-gated
potassium channels (Kv1.5, Kv11.1) and other mammalian
proteins (63, 64).
The azole class of antifungals has been reported to possess
anti-TB activity. Byrne and colleagues reported that
ketoconazole inhibited growth of Mtb in broth (12).
Furthermore, they observed a 3.42 log CFU reduction in
bacterial load in lungs of Mtb-infected mice that were treated
with ketoconazole-RIF-INH-pyrazinamide (PZA), and a 3.08 log
CFU reduction in mice that were treated with RIF-INH-PZA,
indicating that ketoconazole is synergistic with current !rst-line
anti-TB drugs (12). Ketoconazole enhances the activity of anti-
TB drugs, at least in part, by inhibiting pregnane X receptor
(PXR), a promiscuous ligand-dependent transcriptional factor
that is activated by steroid and xenobiotic agents (65, 66). PXR
modulates expression of mammalian drug ef"ux and metabolism
genes and reduces the ef!cacy of rifamycins against intracellular
Mtb (67). The role of ketoconazole in the treatment of TB should
be explored further.
Clofazimine
Clofazimine is a riminophenazine dye that is used as a !rst line
agent in the treatment of leprosy, in combination with RIF and
dapsone (68). It kills mycobacteria by disrupting multiple
physiological processes, including respiration and K+ transport
across the PM (68). It was originally developed as an anti-TB
drug more than !ve decades ago, but proved to be inferior to RIF
and INH (68). The use of clofazimine to treat TB was revisited
recently, and clofazimine has been listed as a second line anti-TB
agent (2). The ef!cacy of various clofazimine-containing
regiments against MDR-TB is currently being assessed in the
BEAT TB, endTB-Q and TB-PRACTECAL clinical trials (2).
Furthermore, pre-clinical studies show that clofazimine could
reduce the duration of treatment of drug-susceptible TB. Tyagi
and colleagues successfully sterilized Mtb-infected mice with a 3-
month course of clofazimine-RIF-INH-PZA-ethambutol (EMB),
but achieved a similar outcome with RIF-INH-PZA-EMB after
treatment for 5 months (69). CLO-FAST, a phase 2 clinical trial
is currently assessing the ef!cacy of a 3-month anti-TB regimen
containing clofazimine and rifapentine against drug-susceptible
TB (2).
In addition to its direct antimycobacterial activity,
clofazimine has recently been shown to enhance host
antimycobacterial responses by inhibiting mammalian Kv1.3
K+ channels, which are highly expressed on effector memory T
(Tem) lymphocytes (70, 71). Singh and colleagues demonstrated
that inhibition of Kv1.3 channels on Tem cells by clofazimine
during BCG vaccination in mice enhanced vaccine ef!cacy by
promoting selective expansion of central memory T (Tcm) cells,
a T-cell subset that is associated with protective anti-TB
responses. Mice that received clofazimine also exhibited
signi!cantly enhanced resistance against TB (71). These
reports suggest Kv1.3 K+ channel blockade as a promising
approach to enhance BCG vaccine ef!cacy in humans.
Progress Towards Clinical Use of Potassium
Channel Blockers as Anti-Tuberculosis Agents
While clofazimine has now been adopted as an anti-TB agent,
there has been no progress towards bringing ketoconazole and
chloroquine into clinical use against TB. Azole antifungals such
as ketoconazole and "uconazole are commonly used to treat
concomitant candida or cryptococcal infections in HIV-infected
TB patients but the impact of azole treatment on TB outcomes
has not been assessed. Ketoconazole is generally well tolerated,
but can cause serious adverse effects such as hepatotoxicity (72).
Rifampicin, isoniazid and pyrazinamide can also cause drug-
induced hepatitis (73), therefore, concomitant use of these anti-
TB drugs with azole antifungals may increase the risk of
hepatotoxicity. The safety of ketoconazole when used as
adjunct treatment for TB requires further investigation.
Sodium Channel Blockers
There is paucity of data on the role of Na+ channels in anti-TB
responses. However, opening of PM Na+ channels leads to in"ux
of Na+ into the cytosol down its chemical gradient, thus reducing
the electrical gradient between the ECF and cytosol. This reduces
the driving force for Ca2+ entry. Most PM Na+ channels may
therefore inhibit host antimycobacterial responses, and several
Na+ channel antagonists including ambroxol, carbamazepine
and valproic acid promote host anti-TB responses (16, 19).
Ambroxol
Ambroxol is an inhibitor of voltage-gated sodium channel (Nav)
1.8 and is primarily used as a mucolytic agent (74). It is a potent
inducer of autophagy and has garnered interest as a potential
therapeutic agent to hasten degradation of misfolded proteins in
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proteinopathies including Parkinson’s disease and primary
alveolar proteinosis (75, 76). It has no direct antimycobacterial
activity (19, 53), but it induces dose-dependent autophagic
control of Mtb in vitro and in vivo and promotes
mycobacterial killing in Mtb-infected primary mouse
macrophages (19). Additionally, Choi and colleagues observed
that ambroxol potentiated the antimycobacterial activity of
rifampicin in a murine TB model, resulting in a three-fold
decrease in bacterial load in mice treated with ambroxol and
RIF relative to mice treated with RIF alone (19). Ambroxol
warrants further evaluation as a HDT to augment and enhance
the ef!cacy of current chemotherapy for TB in humans.
Carbamazepine
Carbamazepine is used to treat epilepsy, schizophrenia and
bipolar disorder. It inhibits the activity of Nav 1.5, thus
indirectly inhibiting the uptake of inositol through Na+-
dependent inositol transporters on the PM (16). Inositol is a
carbocyclic sugar upstream to biosynthesis of inositol-1,4,5-
trisphosphate (IP3), a lipid second messenger that activates
IP3Rs on ER. Blockade of inositol uptake by carbamazepine
therefore reduces cytosolic levels of IP3, leading to decreased
Ca2+ release from the ER and upregulation of autophagy (16).
Treatment of MDR-TB-infected mice with carbamazepine for 30
days resulted in a ten-fold decrease in pulmonary bacterial load,
improved lung pathology and stimulated adaptive immunity.
This was achieved through induction of autophagic killing of
intracellular Mtb, mediated by cellular depletion of inositol and
independent of mTOR (16).
Valproic acid
Valproic acid is an inhibitor of Navs, and is used to treat epilepsy,
migraine and bipolar disorder (77, 78). It is active against Mtb in
broth through mechanisms that have not been fully elucidated
(20). Rao and colleagues observed a 1.5 log CFU reduction in
bacterial load following treatment of intracellular Mtb with
valproic acid or INH, and a 2 log CFU reduction when the two
drugs were used together (20). Like carbamazepine, valproic acid
promotes autophagy by interfering with biosynthesis of IP3 (79).
In addition, it inhibits host histone deacetylase 1 (HDAC1), a
protein that is usually upregulated in Mtb-infected macrophages
(80, 81). HDACs suppress gene expression by promoting
chromatin packaging, thus making a segment of DNA
inaccessible to the cellular transcription machinery (82).
Upregulating HDAC1 in Mtb-infected macrophages reduces
expression of IL-12b, a cytokine important in the initiation of
Th1 responses (80). Therefore, repurposing of carbamazepine
and valproic acid as adjunct HDTs to enhance intracellular
killing of Mtb by current anti-TB drugs should be explored as
a treatment option for human TB.
Progress Towards Clinical Use of Sodium Channel
Blockers as Anti-Tuberculosis Agents
The use of ambroxol, carbamazepine and valproic acid against
TB has not been tested in a clinical trial setting. Carbamazepine
and valproic acid are used widely as treatment for epilepsy in
low- and middle-income countries where the burden of TB is
high. However, the impact of concomitant use of sodium channel
blockers and anti-TB treatment on TB outcomes has not been
evaluated. Furthermore, both carbamazepine and valproic acid
have been shown to cause hepatotoxicity in some individuals (83,
84), but there are no clinical trial data on the safety of
carbamazepine and valproic when used in combination with
existing anti-TB drugs.
Other Ion Channel Blockers
Fluoxetine
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and
is primarily used as an anti-depressant. However, "uoxetine also
has antiviral, antibacterial and immunomodulatory properties
(85–87). In addition to inhibiting the uptake of serotonin into
pre-synaptic neurons, "uoxetine modulates the activity of
VGCCs, K2P, Navs and 5-hydrotryptamine 3 (5-HT3) (88–90).
Schump and colleagues observed a 50% reduction in growth
of intracellular Mtb following treatment with "uoxetine, even
though it had limited activity against Mtb in broth (91). Several
mechanisms for this have been described, including
accumulation inside macrophages and induction of autophagy
(15, 91). In another study, Stanley and colleagues demonstrated
that "uoxetine promoted secretion of TNF-a, induced
autophagy and inhibited growth of intracellular Mtb by 75% in
J774 cells (15). These observations merit evaluation of the anti-
TB activity of "uoxetine in clinical studies of human TB.
Phenothiazines
Phenothiazines are a large group of heterocyclic molecules most
widely used as antipsychotics and antihistamines due to their
abil ity to modulate dopamine signaling (92). Most
phenothiazines bind to and modulate the activity of multiple
mammalian proteins, including ligand-gated ion channels, ion
pumps, G protein-coupled receptors and ef"ux pumps (92, 93).
The antimycobacterial properties of phenothiazines have
been known for decades, but they were overshadowed by the
current !rst line anti-TB compounds, to which they are inferior
(7). However, the rise of MDR-TB has rekindled interest in the
use of phenothiazines against Mtb. Most phenothiazines are
active against extracellular Mtb at concentrations that cannot
be achieved safely in vivo. However, they are generally active
against intracellular Mtb at much lower concentrations (94).
Some phenothiazines are concentrated by macrophages to at
least 10 times their plasma concentrations, which may partly
explain their potency against intracellular Mtb (94–96).
Thioridazine, chlorpromazine, promethazine, methyldiazine
and tri"uoperazine are among the phenothiazines that have
shown the most promise as potential anti-TB agents.
Thioridazine was once a popular drug for schizophrenia and
psychosis but has largely been replaced by the newer generation
of neuroleptics. It kills extracellular Mtb by disrupting ATP
synthesis (17, 97). Machado and colleagues demonstrated that
thioridazine promotes acidi!cation of Mtb phagosomes, and
reported an 88% increase in Mtb killing by thioridazine-treated
macrophages (17). As thioridazine has multiple eukaryotic
protein targets, the mechanism through which it promotes
phagosome acidi!cation has not been elucidated. However, one
Mitini-Nkhoma et al. Ion Channel Blockers for TB
Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6657856
possible explanation is that it inhibits the ef"ux of ions from the
phagolysosome, leading to indirect acidi!cation (98).
In addition, thioridazine inhibits mycobacterial drug ef"ux
systems, reduces resistance levels of different strains of MDR-TB
to !rst and second-line anti-TB agents, and hastens clearance of
drug-susceptible Mtb by !rst-line anti-TB agents (17, 95, 99).
Dutta and colleagues were able to sterilize lungs of mice infected
with drug-susceptible Mtb with a 4 month course of
thioridazine-RIF-INH-PZA, but achieved the same with RIF-
INH-PZA in 5 months (95).
Progress Towards Clinical Use of Other Ion Channel
Blockers as Anti-Tuberculosis Agents
Fluoxetine and phenothiazines are currently not used as anti-TB
drugs in clinical practice. However, thioridazine is relatively well
tolerated, and has received more attention as a potential anti-TB
agent than any other phenothiazine. There is need for clinical
trials to determine the ef!cacy of thioridazine as part of anti-TB
treatment regimens in humans.
SUMMARY AND CONCLUDING REMARKS
Ion channel blockers have the potential to contribute to the
treatment of TB to reduce morbidity and mortality from the
disease. Their ability to enhance the activity of !rst-line anti-TB
drugs could help hasten clearance of Mtb from lungs of
individuals with pulmonary TB disease, reduce transmission of
infection, emergency of drug-resistant mutants and relapse rates.
The ideal host-directed therapeutics for TB should potentiate the
immune system’s antimycobacterial defenses while preventing
excessive in"ammation and tissue injury. In addition to
enhancing clearance of Mtb, ion channel blockers generally
attenuate host in"ammatory responses and may reduce tissue
injury in TB patients. In the absence of a single agent that can
eliminate Mtb, combination therapy will remain the mainstay of
TB treatment. While current drug combinations are designed to
maximize clearance of Mtb by targeting the pathogen, ion
channel blockers could enhance bacillary clearance by targeting
both the pathogen and the host immune response. The reduction
in the risk of active TB associated with the use of dihydropyridine
calcium channel blockers is a cause for optimism and may pave
the way for clinical trials of ion channel blockers as adjunct
treatment for human TB.
AUTHOR CONTRIBUTIONS
SM-N wrote the manuscript with input from HM and DT.
All authors contributed to the article and approved the
submitted version.
FUNDING
HM and KJ are supported by African Research Leader Awards
MR/P020526/1 and MR/T008822/1, respectively, jointly funded
by the UK MRC and DFID under the MRC/DFID Concordant
agreement. HCM is also supported by BMGF and NIH through
grant numbers OPP1108452 and RO1AI155319, respectively.
Wellcome Trust Core Funding Award number 206545/Z/17/Z
supports the Malawi Liverpool Wellcome Trust Clinical
Research Programme.
REFERENCES
1. Hershkovitz I, Donoghue HD, Minnikin DE, Besra GS, Lee OYC, Gernaey AM,
et al. Detection and Molecular Characterization of 9000-Year-Old
Mycobacterium tuberculosis From a Neolithic Settlement in the Eastern
Mediterranean. PLoS One (2008) 3(10):e3426. doi: 10.1371/journal.pone.0003426
2. World Health Organization. Global Tuberculosis Report 2020. Geneva: World
Health Organisation (2020). Licence: CC BY-NC-SA 3.0 IGO.
3. Sotgiu G, Centis R, D’Ambrosio L, Migliori GB. Tuberculosis Treatment and
Drug Regimens. Cold Spring Harb Perspect Med (2015) 5(5):a017822.
doi: 10.1101/cshperspect.a017822
4. Mekonnen HS, Azagew AW. Non-Adherence to Anti-Tuberculosis
Treatment, Reasons and Associated Factors Among TB Patients Attending
at Gondar Town Health Centers, Northwest Ethiopia. BMC Res Notes (2018)
11(1):691. doi: 10.1186/s13104-018-3789-4
5. Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. Side Effects
Associated With the Treatment of Multidrug-Resistant Tuberculosis at a
Tuberculosis Referral Hospital in South Korea: A Retrospective Study.
Medicine (Baltimore) (2017) 96(28):e7482. doi: 10.1097/MD.0000000000007482
6. Crowle AJ, May MH. Inhibition of Tubercle Bacilli in Cultured Human
Macrophages by Chloroquine Used Alone and in Combination With
Streptomycin, Isoniazid, Pyrazinamide, and Two Metabolites of Vitamin
D3. Antimicrob Agents Chemother (1990) 34(11):2217–22. doi: 10.1128/
AAC.34.11.2217
7. Crowle AJ, Douvas GS, May MH. Chlorpromazine: A Drug Potentially Useful
for Treating Mycobacterial Infections. Chemotherapy (1992) 38(6):410–9.
doi: 10.1159/000239036
8. Klemens SP, DeStefano MS, Cynamon MH. Therapy of Multidrug-Resistant
Tuberculosis: Lessons From Studies With Mice. Antimicrob Agents
Chemother (1993) 37(11):2344–7. doi: 10.1128/AAC.37.11.2344
9. Gollapudi S, Reddy M, Gangadharam P, Tsuruo T, Gupta S. Mycobacterium
Tuberculosis Induces Expression of P-glycoprotein in Promonocytic U1 Cells
Chronically InfectedWith HIV Type 1. Biochem Biophys Res Commun (1994)
199(3):1181–7. doi: 10.1006/bbrc.1994.1355
10. Grange JM, Snell NJC. Activity of Bromhexine and Ambroxol, Semi-Synthetic
Derivatives of Vasicine From the Indian Shrub Adhatoda Vasica, Against
Mycobacterium tuberculosis In Vitro. J Ethnopharmacol (1996) 50(1):49–53.
doi: 10.1016/0378-8741(95)01331-8
11. Esiobu N, Hoosein N. An Assessment of the In Vitro Antimicrobial Effects of
Two Antiepileptic Drugs - Sodium Valproate and Phenytoin. Antonie van
Leeuwenhoek (2003) 83(1):63–8. doi: 10.1023/A:1022992224594
12. Byrne ST, Denkin SM, Gu P, Nuermberger E, Zhang Y. Activity of
Ketoconazole Against Mycobacterium tuberculosis In Vitro and in the
Mouse Model. J Med Microbiol (2007) 56(Pt 8):1047–51. doi: 10.1099/
jmm.0.47058-0
13. Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al.
Short, Highly Effective, and Inexpensive Standardized Treatment of
Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med (2010) 182
(5):684–92. doi: 10.1164/rccm.201001-0077OC
14. Smolarz HD, Swatko-Ossor M, Ginalska G, Medynska E. Antimycobacterial
Effect of Extract and its Components From Rheum Rhaponticum. J AOAC Int
(2013) 96(1):155–60. doi: 10.5740/jaoacint.12-010
15. Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, et al.
Identi!cation of Host-Targeted Small Molecules That Restrict Intracellular
Mitini-Nkhoma et al. Ion Channel Blockers for TB
Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6657857
Mycobacterium Tuberculosis Growth. PLoS Pathog (2014) 10(2):e1003946.
doi: 10.1371/journal.ppat.1003946
16. Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, et al.
Functional Drug Screening Reveals Anticonvulsants as Enhancers of mTOR-
Independent Autophagic Killing of Mycobacterium Tuberculosis Through
Inositol Depletion. EMBO Mol Med (2015) 7(2):127–39. doi: 10.15252/
emmm.201404137
17. Machado D, Pires D, Perdigão J, Couto I, Portugal I, Martins M, et al. Ion
Channel Blockers as Antimicrobial Agents, Ef"ux Inhibitors, and Enhancers
of Macrophage Killing Activity Against Drug Resistant Mycobacterium
tuberculos is . PLoS One (2016) 11(2) :e0149326. doi : 10.1371/
journal.pone.0149326
18. World Health Organisation. WHO Treatment Guidelines for Drug-Resistant
Tuberculosis : 2016 Update. Geneva: World Health Organisation (2016).
19. Choi SW, Gu Y, Peters RS, Salgame P, Ellner JJ, Timmins GS, et al. Ambroxol
Induces Autophagy and Potentiates Rifampin Antimycobacterial Activity.
Antimicrob Agents Chemother (2018) 62(9):e01019–18. doi: 10.1128/
aac.01019-18
20. Rao M, Valentini D, Zumla A, Maeurer M. Evaluation of the Ef!cacy of
Valproic Acid and Suberoylanilide Hydroxamic Acid (Vorinostat) in
Enhancing the Effects of First-Line Tuberculosis Drugs Against Intracellular
Mycobacterium tuberculosis. Int J Infect Dis (2018) 69:78–84. doi: 10.1016/
j.ijid.2018.02.021
21. Roca FJ, Whitworth LJ, Redmond S, Jones AA, Ramakrishnan L. TNF Induces
Pathogenic Programmed Macrophage Necrosis in Tuberculosis Through a
Mitochondrial-Lysosomal-Endoplasmic Reticulum Circuit. Cell (2019) 178
(6):1344–1361.e11. doi: 10.1016/j.cell.2019.08.004
22. Yang H, Hu J, Chen YJ, Ge B. Role of Sirt1 in Innate Immune Mechanisms
Against Mycobacterium Tuberculosis Via the Inhibition of TAK1 Activation.
Arch Biochem Biophys (2019) 667:49–58. doi: 10.1016/j.abb.2019.04.006
23. Lee CC, Lee MTG, Hsu WT, Park JY, Porta L, Liu MA, et al. Use of Calcium
Channel Blockers and Risk of Active Tuberculosis Disease: A Population-
Based Analysis. Hypertension (2021) 77(2):328–37. doi: 10.1161/
HYPERTENSIONAHA.120.15534
24. Newton AC, Bootman MD, Scott JD. Second Messengers. Cold Spring Harb
Perspect Biol (2016) 8(8):a005926. doi: 10.1101/cshperspect.a005926
25. Clapham DE. Calcium Signaling. Cell (2007) 131(6):1047–58. doi: 10.1016/
j.cell.2007.11.028
26. Biswas D, Qureshi OS, Lee WY, Croudace JE, Mura M, Lammas DA. ATP-
Induced Autophagy Is Associated With Rapid Killing of Intracellular
Mycobacteria Within Human Monocytes/Macrophages. BMC Immunol
(2008) 9:35. doi: 10.1186/1471-2172-9-35
27. Kondratskyi A, Kondratska K, Skryma R, Prevarskaya N. Ion Channels in the
Regulation of Apoptosis. Biochim Biophys Acta (2015) 1848(10 Pt B):2532–46.
doi: 10.1016/j.bbamem.2014.10.030
28. Kondratskyi A, Kondratska K, Skryma R, Klionsky DJ, Prevarskaya N. Ion
Channels in the Regulation of Autophagy. Autophagy (2018) 14(1):3–21.
doi: 10.1080/15548627.2017.1384887
29. Hamilton SL. Ryanodine Receptors. Cell Calcium (2005) 38(3-4):253–60.
doi: 10.1016/j.ceca.2005.06.037
30. Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, But Not Necrosis,
of Infected Monocytes Is Coupled With Killing of Intracellular Bacillus
Calmette-Gue!rin. J Exp Med (1994) 180(4):1499–509. doi: 10.1084/
jem.180.4.1499
31. Kumar S, Birge RB. Efferocytosis. Curr Biol (2016) 26(13):R558–9.
doi: 10.1016/j.cub.2016.01.059
32. Divangahi M, Behar SM, Remold H. Dying to Live: How the Death Modality
of the Infected Macrophage Modulates Immunity to Tuberculosis. Adv Exp
Med Biol (2013) 783:103–20. doi: 10.1007/978-1-4614-6111-1_6
33. Vervliet T. Ryanodine Receptors in Autophagy: Implications for
Neurodegenerative Diseases? Front Cell Neurosci (2018) 12:89.
doi: 10.3389/fncel.2018.00089
34. Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine do You Have to
Drink to Stay Healthy? Adv Nutr (2016) 7(4):706–18. doi: 10.3945/
an.115.011627
35. Koushki M, Amiri-Dashatan N, Ahmadi N, Abbaszadeh HA, Rezaei-Tavirani
M. Resveratrol: A Miraculous Natural Compound for Diseases Treatment.
Food Sci Nutr (2018) 6(8):2473–90. doi: 10.1002/fsn3.855
36. McCalley AE, Kaja S, Payne AJ, Koulen P. Resveratrol and Calcium Signaling:
Molecular Mechanisms and Clinical Relevance. Molecules (2014) 19(6):7327–
40. doi: 10.3390/molecules19067327
37. Coimbra ES, Santos JA, Lima LL, Machado PA, Campos DL, Pavan FR, et al.
Synthesis, Antitubercular and Leishmanicidal Evaluation of Resveratrol
Analogues. J Braz Chem Soc (2016) 27(12):2161–9. doi: 10.5935/0103-
5053.20160107
38. Vestergaard M, Ingmer H. Antibacterial and Antifungal Properties of
Resveratrol. Int J Antimicrob Agents (2019) 53(6):716–23. doi: 10.1016/
j.ijantimicag.2019.02.015
39. Zumla A, Rao M, Dodoo E, Maeurer M. Potential of Immunomodulatory
Agents as Adjunct Host-Directed Therapies for Multidrug-Resistant
Tuberculosis. BMC Med (2016) 14:89. doi: 10.1186/s12916-016-0635-1
40. Cheng CY, Gutierrez NM, Marzuki MB, Lu X, Foreman TW, Paleja B, et al.
Host Sirtuin 1 Regulates Mycobacterial Immunopathogenesis and Represents
a Therapeutic Target Against Tuberculosis. Sci Immunol (2017) 2(9):eaaj1789.
doi: 10.1126/sciimmunol.aaj1789
41. Liu T, Zhang L, Joo D, Sun SC. NF-kB Signaling in In"ammation. Signal
Transduct Target Ther (2017) 2:17023. doi: 10.1038/sigtrans.2017.23
42. Aronica MA, Mora AL, Mitchell DB, Finn PW, Johnson JE, Sheller JR, et al.
Preferential Role for NF-kB/Rel Signaling in the Type 1 But Not Type2 T Cell-
Dependent Immune Response In Vivo. J Immunol (1999) 163(9):5116–24.
43. Bai X, Feldman NE, Chmura K, Ovrutsky AR, Su WL, Grif!n L, et al.
Inhibition of Nuclear Factor-Kappa B Activation Decreases Survival of
Mycobacterium Tuberculosis in Human Macrophages. PLoS One (2013) 8
(4):e61925. doi: 10.1371/journal.pone.0061925
44. Gupta S, Salam N, Srivastava V, Singla R, Behera D, Khayyam KU, et al.
Voltage Gated Calcium Channels Negatively Regulate Protective Immunity to
Mycobacterium tuberculosis. PLoS One (2009) 4(4):e5305. doi: 10.1371/
journal.pone.0005305
45. Paik S, Kim JK, Chung C, Jo EK. Autophagy: A New Strategy for Host-
Directed Therapy of Tuberculosis. Virulence (2019) 10(1):448–59.
doi: 10.1080/21505594.2018.1536598
46. Jua!rez E, Carranza C, Sa!nchez G, Gonza!lez M, Cha!vez J, Torres M, et al.
Autophagy Inducing Drugs Contribute to Control Mycobacterium Tuberculosis
Infection. Front Immunol. doi: 10.3389/conf.!mmu.2015.05.00160. Conference
Abstract: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American
Association of Immunology - 10o. Congreso de la Asociacio!n Colombiana de
Alergia, Asma e Inmunologı !a.
47. Jua!rez E, Carranza C, Sa!nchez G, Gonza!lez M, Cha!vez J, Sarabia C, et al.
Loperamide Restricts Intracellular Growth of Mycobacterium Tuberculosis in
Lung Macrophages. Am J Respir Cell Mol Biol (2016) 55(6):837–47.
doi: 10.1165/rcmb.2015-0383OC
48. Shan HL, Wang Y, Wu JW, Hang PZ, Li X, Sun LH, et al. Verapamil Reverses
Cardiac Iron Overload in Streptozocin-Induced Diabetic Rats. Naunyn
Schmiedebergs Arch Pharmacol (2013) 386(7):645–50. doi: 10.1007/s00210-
013-0863-2
49. Ludwiczek S, Theurl I, Muckenthaler MU, Jakab M, Mair SM, Theurl M, et al.
Ca2+ Channel Blockers Reverse Iron Overload by a New Mechanism Via
Divalent Metal Transporter-1. Nat Med (2007) 13(4):448–54. doi: 10.1038/
nm1542
50. Zhang L, Hendrickson RC, Meikle V, Lefkowitz EJ, Ioerger TR, Nierderweis
M. Comprehensive Analysis of Iron Utilization by Mycobacterium
Tuberculosis . PLoS Pathog (2020) 16(2):e1008337. doi: 10.1371/
journal.ppat.1008337
51. Jahng JWS, Alsaadi RM, Palanivel R, Song E, Hipolito VEB, Sung HK, et al.
Iron Overload Inhibits Late Stage Autophagic Flux Leading to Insulin
Resistance. EMBO Rep (2019) 20(10):e47911. doi: 10.15252/embr.201947911
52. Chen C, Gardete S, Jansen RS, Shetty A, Dick T, Rhee KY, et al. Verapamil
Targets Membrane Energetics in Mycobacterium tuberculosis. Antimicrob
Agents Chemother (2018) 62(5):e02107. doi: 10.1128/AAC.02107-17
53. Mitini-Nkhoma SC, Fernando N, Ishaka GKD, Handunnetti SM, Pathirana
SL. Ion Transport Modulators as Antimycobacterial Agents. Tuberc Res Treat
(2020) 2020:1–7. doi: 10.1155/2020/3767915
54. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR.
Acceleration of Tuberculosis Treatment by Adjunctive Therapy With
Verapamil as an Ef"ux Inhibitor. Am J Respir Crit Care Med (2013) 188
(5):600–7. doi: 10.1164/rccm.201304-0650OC
Mitini-Nkhoma et al. Ion Channel Blockers for TB
Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6657858
55. Wedel DJ, Quinlan JG, Iaizzo PA. Clinical Effects of Intravenously
Administered Dantrolene. Mayo Clin Proc (1995) 70(3):241–6. doi: 10.
4065/70.3.241
56. Lewis RS, Cahalan MD. Potassium and Calcium Channels in Lymphocytes.
Annu Rev Immunol (1995) 13:623–53. doi: 10.1146/annurev.iy.13.040
195.003203
57. Hou P, Zhang R, Liu Y, Feng J, Wang W, Wu Y, et al. Physiological Role of
Kv1.3 Channel in T Lymphocyte Cell Investigated Quantitatively by Kinetic
Modeling. PLoS One (2014) 9(3):e89975. doi: 10.1371/journal.pone.0089975
58. Kazama I. Targeting Lymphocyte Kv1.3-Channels to Suppress Cytokine
Storm in Severe COVID-19: Can it be a Novel Therapeutic Strategy? Drug
Discov Ther (2020) 14(3):143–4. doi: 10.5582/ddt.2020.03046
59. Mishra R, Kohli S, Malhotra N, Bandyopadhyay P, Mehta M, Munshi M, et al.
Targeting Redox Heterogeneity to Counteract Drug Tolerance in Replicating
Mycobacterium Tuberculosis. Sci Transl Med (2019) 11(518):eaaw6635.
doi: 10.1126/scitranslmed.aaw6635
60. Matt U, Müller R, Müller D, Stenziger A, Zinkernagel A, Seelig A, et al.
Chloroquine as a Potential Adjunctive Therapy in Tuberculosis. Eur Respir J
(2014) 44(Suppl 58):1896.
61. Matt U, Selchow P, Dal Molin M, Strommer S, Sharif O, Schilcher K, et al.
Chloroquine Enhances the Antimycobacterial Activity of Isoniazid and
Pyrazinamide by Reversing In"ammation-Induced Macrophage Ef"ux. Int J
Antimicrob Agents (2017) 50(1):55–62. doi: 10.1016/j.ijantimicag.2017.02.022
62. te Brake LHM, de Knegt GJ, de Steenwinkel JE, van Dam TJP, Burger DM,
Russel FGM, et al. The Role of Ef"ux Pumps in Tuberculosis Treatment and
Their Promise as a Target in Drug Development: Unraveling the Black Box.
Annu Rev Pharmacol Toxicol (2018) 58:271–91. doi: 10.1146/annurev-
pharmtox-010617-052438
63. Zonios DI, Bennett JE. Update on Azole Antifungals. Semin Respir Crit Care
Med (2008) 29(2):198–210. doi: 10.1055/s-2008-1063858
64. Dumaine R, Roy ML, Brown AM. Blockade of HERG and Kv1.5 by
Ketoconazole. J Pharmacol Exp Ther (1998) 286(2):727–35.
65. Pavek P. Pregnane X Receptor (PXR)-Mediated Gene Repression and Cross-
Talk of PXR With Other Nuclear Receptors Via Coactivator Interactions.
Front Pharmacol (2016) 7:456. doi: 10.3389/fphar.2016.00456
66. Bhagyaraj E, Tiwari D, Ahuja N, Nanduri R, Saini A, Kalra R, et al. A Human
Xenobiotic Nuclear Receptor Contributes to Nonresponsiveness of
Mycobacterium tuberculosis to the Antituberculosis Drug Rifampicin. J Biol
Chem (2018) 293(10):3747–57. doi: 10.1074/jbc.M117.818377
67. Shehu AI, Li G, Xie W, Ma X. The Pregnane X Receptor in Tuberculosis
Therapeutics. Expert Opin Drug Metab Toxicol (2016) 12(1):21–30.
doi: 10.1517/17425255.2016.1121381
68. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R.
Clofazimine: Current Status and Future Prospects. J Antimicrob Chemother
(2012) 67(2):290–8. doi: 10.1093/jac/dkr444
69. Tyagi S, Ammerman NC, Li SY, Adamson J, Converse PJ, Swanson RV, et al.
Clofazimine Shortens the Duration of the First-Line Treatment Regimen for
Experimental Chemotherapy of Tuberculosis. Proc Natl Acad Sci U S A (2015)
112(3):869–74. doi: 10.1073/pnas.1416951112
70. Ren YR, Pan F, Parvez S, Fleig A, Chong CR, Xu J, et al. Clofazimine Inhibits
Human Kv1.3 Potassium Channel by Perturbing Calcium Oscillation in T
Lymphocytes. PLoS One (2008) 3(12):e4009. doi: 10.1371/journal.
pone.0004009
71. Singh DK, Dwivedi VP, Ranganathan A, Bishai WR, Van Kaer L, Das G.
Blockade of the Kv1.3 K+ Channel Enhances BCG Vaccine Ef!cacy by
Expanding Central Memory T Lymphocytes. J Infect Dis (2016) 214
(9):1456–64. doi: 10.1093/infdis/jiw395
72. Heiberg JK, Svejgaard E. Toxic Hepatitis During Ketoconazole Treatment. Br
Med J (Clin Res Ed) (1981) 283(6295):825–6. doi: 10.1136/bmj.283.6295.825
73. Askgaard DS, Wilcke T, Dossing M. Hepatotoxicity Caused by the Combined
Action of Isoniazid and Rifampicin. Thorax (1995) 50(2):213–4. doi: 10.1136/
thx.50.2.213
74. Lef"er A, Reckzeh J, Nau C. Block of Sensory Neuronal Na+ Channels by the
Secreolytic Ambroxol Is Associated With an Interaction With Local
Anesthetic Binding Sites. Eur J Pharmacol (2010) 630(1-3):19–28.
doi: 10.1016/j.ejphar.2009.12.027
75. Oda N, Tamai K, Suzuki Y, Yoshimatsu H, Matsuoka H, Matsumoto Y, et al.
Marked Improvement in Autoimmune Pulmonary Alveolar Proteinosis With
Severe Hypoxemia in a Patient Treated With Ambroxol: A Case Report. J Med
Case Rep (2015) 9:100. doi: 10.1186/s13256-015-0588-6
76. Mullin S, Smith L, Lee K, D’Souza G, Woodgate P, El"ein J, et al. Ambroxol
for the Treatment of Patients With Parkinson Disease With and Without
Glucocerebrosidase GeneMutations: A Nonrandomized, Noncontrolled Trial.
JAMA Neurol (2020) 77(4):427–34. doi: 10.1001/jamaneurol.2019.4611
77. Ghodke-Puranik Y, Thorn CF, Lamba JK, Leeder JS, Song W, Birnbaum AK,
et al. Valproic Acid Pathway: Pharmacokinetics and Pharmacodynamics.
Pharmacogenet Genomics (2013) 23(4):236–41. doi: 10.1097/FPC.0b013e
32835ea0b2
78. Zanatta G, Sula A, Miles AJ, Ng LCT, Torella R, Pryde DC, et al. Valproic
Acid Interactions With the NavMs Voltage-Gated Sodium Channel. Proc
Natl Acad Sci U S A (2019) 116(52):26549–54. doi: 10.1073/pnas.
1909696116
79. Ji MM, Wang L, Zhan Q, Xue W, Zhao Y, Zhao X, et al. Induction of
Autophagy by Valproic Acid Enhanced Lymphoma Cell Chemosensitivity
Through HDAC-Independent and IP3-Mediated PRKAA Activation.
Autophagy (2015) 11(12):2160–71. doi: 10.1080/15548627.2015.1082024
80. Chandran A, Antony C, Jose L, Mundayoor S, Natarajan K, Kumar RA.
Mycobacterium tuberculosis Infection Induces HDAC1-Mediated Suppression
of IL-12B Gene Expression in Macrophages. Front Cell Infect Microbiol (2015)
5:90. doi: 10.3389/fcimb.2015.00090
81. Soria-Castro R, Schcolnik-Cabrera A, Rodrı !guez-Lo!pez G, Campillo-Navarro
M, Puebla-Osorio N, Estrada-Parra S, et al. Exploring the Drug Repurposing
Versatility of Valproic Acid as a Multifunctional Regulator of Innate and
Adaptive Immune Cells. J Immunol Res (2019) 2019:9678098. doi: 10.1155/
2019/9678098
82. Gatla HR, Muniraj N, Thevkar P, Yavvari S, Sukhavasi S, Makena MR.
Regulation of Chemokines and Cytokines by Histone Deacetylases and an
Update on Histone Decetylase Inhibitors in Human Diseases. Int J Mol Sci
(2019) 20(5):1110. doi: 10.3390/ijms20051110
83. Kalapos MP. Carbamazepine-Provoked Hepatotoxicity and Possible
Aetiopathological Role of Glutathione in the Events: Retrospective Review
of Old Data and Call for New Investigation. Adverse Drug React Toxicol Rev
(2002) 21(3):123–41. doi: 10.1007/BF03256188
84. Gayam V, Mandal AK, Khalid M, Shrestha B, Garlapati P, Khalid M. Valproic
Acid Induced Acute Liver Injury Resulting in Hepatic Encephalopathy- A
Case Report and Literature Review. J Community Hosp Intern Med Perspect
(2018) 8(5):311–4. doi: 10.1080/20009666.2018.1514933
85. Di Rosso ME, Palumbo ML, Genaro AM. Immunomodulatory Effects of
Fluoxetine: A New Potential Pharmacological Action for a Classic
Antidepressant Drug? Pharmacol Res (2016) 109:101–7. doi: 10.1016/
j.phrs.2015.11.021
86. Karine de Sousa A, Rocha JE, Gonc"alves de Souza T, Sampaio de Freitas T,
Ribeiro-Filho J, Melo Coutinho HD. New Roles of Fluoxetine in
Pharmacology: Antibacterial Effect and Modulation of Antibiotic Activity.
Microb Pathog (2018) 123:368–71. doi: 10.1016/j.micpath.2018.07.040
87. Bauer L, Manganaro R, Zonsics B, Strating JRPM, El Kazzi P, Lorenzo Lopez
M, et al. Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C
Protein in a Stereospeci!c Manner. ACS Infect Dis (2019) 5(9):1609–23.
doi: 10.1021/acsinfecdis.9b00179
88. Poulin H, Bruhova I, Timour Q, Theriault O, Beaulieu JM, Frassati D, et al.
Fluoxetine Blocks Nav1.5 Channels Via a Mechanism Similar to That of Class
1 Antiarrhythmics. Mol Pharmacol (2014) 86(4):378–89. doi: 10.1124/
mol.114.093104
89. Be!try C, Etie!vant A, Oosterhof C, Ebert B, Sanchez C, Haddjeri N. Role of 5-
HT3 Receptors in the Antidepressant Response. Pharmaceuticals (2011) 4
(4):603–29. doi: 10.3390/ph4040603
90. Dong YY, Pike ACW, Mackenzie A, McClenaghan C, Aryal P, Dong L, et al.
K2P Channel Gating Mechanisms Revealed by Structures of TREK-2 and a
Complex With Prozac. Science (2015) 347(6227):1256–9. doi: 10.1126/
science.1261512
91. Schump MD, Fox DM, Bertozzi CR, Riley LW. Subcellular Partitioning and
Intramacrophage Selectivity of Antimicrobial Compounds Against
Mycobacterium Tuberculosis. Antimicrob Agents Chemother (2017) 61(3):
e01639–16. doi: 10.1128/AAC.01639-16
92. Jaszczyszyn A, Ga! siorowski K, S!wia! tek P, Malinka W, Cies!lik-Boczula K,
Petrus J, et al. Chemical Structure of Phenothiazines and Their Biological
Mitini-Nkhoma et al. Ion Channel Blockers for TB
Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 6657859
Activity. Pharmacol Rep (2012) 64(1):16–23. doi: 10.1016/S1734-1140(12)
70726-0
93. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, ChenMY, et al. Pharmacological
Exploitation of the Phenothiazine Antipsychotics to Develop Novel
Antitumor Agents-A Drug Repurposing Strategy. Sci Rep (2016) 6:27540.
doi: 10.1038/srep27540
94. Viveiros M, Amaral L. Enhancement of Antibiotic Activity Against Poly-Drug
Resistant Mycobacterium tuberculosis by Phenothiazines. Int J Antimicrob
Agents (2001) 17(3):225–8. doi: 10.1016/S0924-8579(00)00343-5
95. Dutta NK, Pinn ML, Karakousis PC. Sterilizing Activity of Thioridazine in
Combination With the First-Line Regimen Against Acute Murine
Tuberculosis. Antimicrob Agents Chemother (2014) 58(9):5567–9.
doi: 10.1128/AAC.03408-14
96. Jiang C, Yang W, Wang C, Qin W, Ming J, Zhang M, et al. Methylene Blue-
Mediated Photodynamic Therapy Induces Macrophage Apoptosis Via ROS
and Reduces Bone Resorption in Periodontitis. Oxid Med Cell Longev (2019)
2019:1529520. doi: 10.1155/2019/1529520
97. Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the Respiration of
Multi-Drug Resistant Clinical Isolates of Mycobacterium Tuberculosis by
Thioridazine: Potential Use for Initial Therapy of Freshly Diagnosed
Tuberculosis. J Antimicrob Chemother (1996) 38(6):1049–53. doi: 10.1093/
jac/38.6.1049
98. Amaral L, Viveiros M. Thioridazine: A Non-Antibiotic Drug Highly Effective,
in Combination With First Line Anti-Tuberculosis Drugs, Against Any Form
of Antibiotic Resistance of Mycobacterium tuberculosis Due to its Multi-
Mechanisms of Action. Antibiotics (2017) 6(1):3. doi: 10.3390/
antibiotics6010003
99. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra
C, Amaral L, et al. The Antipsychotic Thioridazine Shows Promising
Therapeutic Activity in a Mouse Model of Multidrug-Resistant
Tuberculosis. PLoS One (2010) 5(9):e12640. doi: 10.1371/journal.
pone.0012640
Con!ict of Interest: The authors declare that the manuscript was written in the
absence of any commercial or !nancial relationships that could be construed as a
potential con"ict of interest.
Copyright © 2021 Mitini-Nkhoma, Chimbayo, Mzinza, Mhango, Chirambo,
Mandalasi, Lakudzala, Tembo, Jambo and Mwandumba. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Mitini-Nkhoma et al. Ion Channel Blockers for TB
Frontiers in Immunology | www.frontiersin.org June 2021 | Volume 12 | Article 66578510
